Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SpoonfulONE is a daily dietary supplement powder and snack product line designed to introduce infants and young children to small, measured amounts of proteins from the 16 foods responsible for over 90% of food allergies. Developed by Dr. Kari Nadeau, a leading pediatric allergist, the product aims to help train children's immune systems to recognize these common allergens as safe foods rather than threats, thereby reducing the risk of developing food allergies. The blend includes peanuts, milk, eggs, tree nuts (almond, cashew, hazelnut, pecan, pistachio, walnut), soy, wheat (oat and wheat), shellfish (shrimp), fish (cod and salmon), and sesame. It is intended for use in children who do not already have diagnosed food allergies or severe eczema. The mechanism relies on early oral exposure—consistent with findings from studies like LEAP—to promote immune tolerance through regular ingestion of allergenic proteins[1][2][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SpoonfulONE.